Evidence-Based Compounds for Anxiety
Anxiety disorders involve hyperactivation of the amygdala, dysregulated GABA and glutamate balance, and chronic HPA axis activation. Evidence-based compounds targeting GABA-A receptors, cortisol signalling, and serotonin pathways show clinical evidence for reducing anxiety severity, physiological stress markers, and perceived anxiety across multiple study designs.
This page presents computational analysis of published research from PubMed/NCBI, BindingDB, and Reactome. Rankings are based on BiohacksAI discovery score, pathway overlap, and study count. This is not medical advice — consult a healthcare professional before starting any supplement.
Browse all compounds · Biological pathways · Molecular targets · All conditions
© Organiq Sweden AB · Patent pending EVE-PAT-2026-001